Immunotherapy Drugs Market
  • ID: 1343
  • April 25, 2019
  • 104 pages
  • Infoholic Research

Global Immunotherapy Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[104 pages report] This market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type (monoclonal antibodies, vaccine, non-specific immunotherapies, adaptive cell therapy, and others), by treatment area (cancer, inflammatory and autoimmune disease, infectious disease, and others), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Immunotherapy Drugs Market
Infoholic’s market research report predicts that the “Global Immunotherapy Drugs Market” will grow at a CAGR of 12.5% during the forecast period. The market has witnessed steady growth in the past few years, and the introduction of novel products has increased the acceptance of immunotherapy drugs in the market. The market is fueled by an upsurge in the incidence of lifestyle and chronic disease globally, reduction in disease recurrence, increasing product approval, and high preference for immunotherapy over traditional chemotherapy.

The growing market trend continues and is becoming one of the increasingly accepted treatments across many countries worldwide. The manufacturers are focusing on new approvals, collaboration, and development of new products due to the increase in demand for immunotherapy drugs for the treatment of cancer and other diseases. Most of the revenue is generated from the leading players in the market with dominant sales such as AbbVie, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Johnson and Johnson, and Merck & Co., Inc.
According to Infoholic Research analysis, North America accounted for the largest share of the global immunotherapy drugs market in 2018. The US dominates the market owing to the presence of most of the immunotherapy drugs manufacturers in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period, owing to factors such as growing incidence of lifestyle diseases, increasing adoption of novel treatment, and low manufacturing cost.
By Drug Type:
• Monoclonal Antibodies (mAbs)
• Vaccines
• Non-specific Immunotherapies
• Adaptive Cell Therapy
• Others
The monoclonal antibodies segment occupied the largest share in 2018 and is expected to grow at low-double-digit CAGR during the forecast period. The adaptive cell therapy segment is expected to grow at a high CAGR during the forecast period 2019–2025.
By Treatment Area:
• Cancer
• Inflammation and Autoimmune Disease
• Infectious Disease
• Others
In 2018, the cancer segment occupied the largest share and is expected to grow at a high CAGR during the forecast period due to the rising incidence of cancer globally and increasing preference for immunotherapy as a first line of treatment.
By Regions:
• North America
• Europe
• APAC
• RoW
North America is dominant in the global immunotherapy drugs market, followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favorable reimbursement policies.
Immunotherapy Drugs Market Research Competitive Analysis – The global immunotherapy drugs market has massive growth opportunities in both developed and developing regions. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.
Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.
For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies. In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks. It is the only treatment specifically designed for migraine prevention to be approved in the European Union. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new products to obtain a high share in the market.
Key Vendors:
• AbbVie, Inc.
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol–Myers Squibb
• Johnson and Johnson
• Merck & Co., Inc.
Key Competitive Facts
• Increasing disease incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the immunotherapy drug development are the major factors driving the market growth.
• With more than 8,000 ongoing trials for cancer immunotherapy, a huge amount of study concentrated on checkpoint inhibitors (CPi) and combinations with chemotherapies, targeted therapies, and other immune-oncology (IO) agents.
Benefits – The report provides complete details about the related sub-segments of the immunotherapy drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the immunotherapy drugs industry.
• Factors influencing the growth of the immunotherapy drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the immunotherapy drugs market in both developed and developing regions.
• Key insights related to major segments of the immunotherapy drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders

Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.1.1 Global Driver for Pharmaceutical Demand 12
1.1.2 R&D Pipeline in Pharmaceutical Industry 12
1.1.3 Top Pharma Drugs by Sales (In $Million) 13
1.2 Industry Trends 14
2 Report Outline 16
2.1 Report Scope 16
2.2 Report Summary 16
2.3 Research Methodology 17
2.4 Report Assumptions 18
3 Market Snapshot 19
3.1 Market Definition – Infoholic Research 19
3.2 Benefits of Immunotherapy 19
3.3 Segmented Addressable Market (SAM) 19
3.4 Trends of the Immunotherapy Drugs Market 20
3.5 Related Markets 21
3.5.1 Human Insulin 21
3.5.2 Oncology Drugs 22
4 Market Outlook 24
4.1 List of Cancer Immunotherapy Drugs Approved (2016- April 2019) 24
4.2 Market segmentation 26
4.3 PEST Analysis 27
4.4 Porter 5 (Five) Forces 28
5 Market Characteristics 29
5.1 DRO – Global Immunotherapy Drugs Market Dynamics 29
5.1.1 Drivers 29
5.1.1.1 High preference of immunotherapy over traditional chemotherapy 29
5.1.1.2 Growing incidence of lifestyle and chronic diseases 30
5.1.2 Opportunities 31
5.1.2.1 Emergence of biosimilars 31
5.1.2.2 Increasing opportunities in the emerging market 31
5.1.3 Restraints 32
5.1.3.1 High immunotherapy treatment costs 32
5.1.3.2 Complex manufacturing process 32
5.2 DRO – Impact Analysis 32
5.3 Key Stakeholders 33
6 Drug Type: Market Size and Analysis 35
6.1 Overview 35
6.2 Monoclonal Antibodies (mAbs) 36
6.3 Vaccine 38
6.4 Non-specific Immunotherapy 39
6.5 Adaptive Cell Therapy 40
6.6 Others 41
7 Treatment Area: Market Size and Analysis 43
7.1 Overview 43
7.2 Cancer 45
7.3 Inflammatory and Autoimmune Diseases 46
7.4 Infectious Disease 47
7.5 Others 48
8 Regions: Market Size and Analysis 50
8.1 Overview 50
8.2 North America 51
8.3 Europe 53
8.4 Asia Pacific 55
8.5 Rest of the World 56
9 Competitive Landscape 58
9.1 Overview 58
10 Vendor Profiles 61
10.1 AbbVie, Inc. 61
10.1.1 Overview 61
10.1.2 Geographic Revenue 63
10.1.3 Business Focus 64
10.1.4 SWOT Analysis 65
10.1.5 Business Strategies 65
10.2 Amgen, Inc. 66
10.2.1 Overview 66
10.2.2 Geographic Revenue 68
10.2.3 Business Focus 69
10.2.4 SWOT Analysis 69
10.2.5 Business Strategies 70
10.3 F. Hoffmann-La Roche Ltd. 70
10.3.1 Overview 70
10.3.2 Business Units 72
10.3.3 Geographic Revenue 73
10.3.4 Business Focus 73
10.3.5 SWOT Analysis 74
10.3.6 Business Strategies 75
10.4 Bristol-Myers Squibb 75
10.4.1 Overview 75
10.4.2 Geographic Revenue 78
10.4.3 Business Focus 79
10.4.4 SWOT Analysis 79
10.4.5 Business Strategy 80
10.5 Johnson & Johnson 81
10.5.1 Overview 81
10.5.2 Business Units 84
10.5.3 Geographic Revenue 85
10.5.4 Business Focus 86
10.5.5 SWOT Analysis 87
10.5.6 Business Strategies 87
10.6 Merck & Co., Inc. 88
10.6.1 Overview 88
10.6.2 Business Units 91
10.6.3 Geographic Revenue 92
10.6.4 Business Focus 93
10.6.5 SWOT Analysis 94
10.6.6 Business Strategies 94
11 Companies to Watch For 95
11.1 Novartis AG 95
11.1.1 Overview 95
11.2 GlaxoSmithKline plc 98
11.2.1 Overview 98
11.3 AstraZeneca PLC 100
11.3.1 Overview 100
11.4 Eli Lilly and Company Ltd 101
11.4.1 Overview 101
12 Annexure 103
12.1 Abbreviations 103

Tables

TABLE 1 LIST OF CANCER IMMUNOTHERAPY DRUGS APPROVED (2016-APRIL 2019) 24
TABLE 2 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY DRUG TYPE, 2018–2025 ($BILLION) 35
TABLE 3 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY TREATMENT AREA, 2018–2025 ($BILLION) 44
TABLE 4 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY REGIONS, 2018–2025 ($BILLION) 51
TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY VENDOR RANKING, 2018 60
TABLE 6 OTHER PROMINENT VENDORS OF IMMUNOTHERAPY DRUGS MARKET 60
TABLE 7 ABBVIE INC.: OFFERINGS 61
TABLE 8 ABBVIE INC.: RECENT DEVELOPMENTS 61
TABLE 9 AMGEN INC.: OFFERINGS 66
TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 66
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 71
TABLE 12 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 71
TABLE 13 BRISTOL-MYERS SQUIBB: OFFERINGS 75
TABLE 14 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 75
TABLE 15 JOHNSON & JOHNSON: PRODUCT OFFERINGS 81
TABLE 16 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 81
TABLE 17 MERCK & CO., INC.: PRODUCT OFFERINGS 88
TABLE 18 MERCK & CO., INC.: RECENT DEVELOPMENTS 89
TABLE 19 NOVARTIS AG: SNAPSHOT 95
TABLE 20 NOVARTIS AG: RECENT DEVELOPMENTS 95
TABLE 21 GLAXOSMITHKLINE PLC: SNAPSHOT 98
TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 98
TABLE 23 ASTRAZENECA PLC: SNAPSHOT 100
TABLE 24 ASTRAZENECA PLC: RECENT DEVELOPMENTS 100
TABLE 25 ELI LILLY AND COMPANY LTD: SNAPSHOT 101
TABLE 26 ELI LILLY AND COMPANY LTD: RECENT DEVELOPMENTS 101

Charts

CHART 1 GLOBAL PRESCRIPTION DRUG SALES, 2018–2025 ($BILLION) 10
CHART 2 GLOBAL OVER-THE-COUNTER DRUG MARKET REVENUE, 2018–2025, $BILLION 10
CHART 3 GLOBAL PHARMA SALES, BIOLOGICS V/S NON-BIOLOGICS (%) 11
CHART 4 GLOBAL PHARMACEUTICAL SALES BY REGION, 2018 12
CHART 5 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2017) 13
CHART 6 PHARMACEUTICAL DRUGS BY SALES, 2018 ($BILLION) 14
CHART 7 RESEARCH METHODOLOGY OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 17
CHART 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE, 2018–2025 ($BILLION) 20
CHART 9 SEGMENTATION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 26
CHART 10 PEST ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 27
CHART 11 PORTER 5 FORCES ON GLOBAL IMMUNOTHERAPY DRUGS MARKET 28
CHART 12 MARKET DYNAMICS – DRO ANALYSIS 29
CHART 13 DRO – IMPACT ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 32
CHART 14 KEY STAKEHOLDERS 33
CHART 15 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2018 AND 2025 ($BILLION) 35
CHART 16 GLOBAL MONOCLONAL ANTIBODY MARKET REVENUE, 2018–2025 ($BILLION) 37
CHART 17 GLOBAL VACCINE MARKET REVENUE, 2018–2025 ($BILLION) 38
CHART 18 GLOBAL NON-SPECIFIC IMMUNOTHERAPY MARKET REVENUE, 2018–2025 ($BILLION) 39
CHART 19 GLOBAL ADAPTIVE CELL THERAPY MARKET REVENUE, 2018–2025 ($BILLION) 41
CHART 20 GLOBAL OTHERS MARKET REVENUE, 2018–2025 ($BILLION) 42
CHART 21 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2018 (%) 43
CHART 22 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2025 (%) 44
CHART 23 GLOBAL CANCER MARKET REVENUE, 2018–2025 ($BILLION) 45
CHART 24 GLOBAL INFLAMMATORY AND AUTOIMMUNE DISEASE MARKET REVENUE, 2018–2025 ($BILLION) 46
CHART 25 GLOBAL INFECTIOUS DISEASE MARKET REVENUE, 2018–2025 ($BILLION) 48
CHART 26 GLOBAL OTHERS MARKET REVENUE, 2018–2025 ($BILLION) 48
CHART 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 50
CHART 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 51
CHART 29 IMMUNOTHERAPY DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($BILLION) 52
CHART 30 IMMUNOTHERAPY DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($BILLION) 54
CHART 31 IMMUNOTHERAPY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($BILLION) 55
CHART 32 IMMUNOTHERAPY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($BILLION) 57
CHART 33 ABBVIE INC.: OVERVIEW SNAPSHOT 62
CHART 34 ABBVIE INC.: GEOGRAPHIC REVENUE 63
CHART 35 ABBVIE INC.: SWOT ANALYSIS 65
CHART 36 AMGEN INC.: OVERVIEW SNAPSHOT 67
CHART 37 AMGEN INC.: GEOGRAPHIC REVENUE 68
CHART 38 AMGEN INC.: SWOT ANALYSIS 69
CHART 39 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 72
CHART 40 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 72
CHART 41 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 73
CHART 42 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 74
CHART 43 BRISTOL-MYERS SQUIBB: OVERVIEW SNAPSHOT 78
CHART 44 BRISTOL-MYERS SQUIBB: GEOGRAPHIC REVENUE 78
CHART 45 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS 79
CHART 46 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 84
CHART 47 JOHNSON & JOHNSON: BUSINESS UNITS 84
CHART 48 JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE 85
CHART 49 JOHNSON & JOHNSON: SWOT ANALYSIS 87
CHART 50 MERCK & CO., INC.: OVERVIEW SNAPSHOT 90
CHART 51 MERCK & CO., INC.: BUSINESS UNITS 91
CHART 52 MERCK & CO., INC.: GEOGRAPHICAL REVENUE 92
CHART 53 MERCK & CO., INC.: SWOT ANALYSIS 94


None

AbbVie, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Johnson and Johnson, and Merck & Co., Inc.

Custom Research

Looking for more specific research study and analysis? Contact our Custom Research Team

Write to Custom Research Team